Download
fimmu-12-706133.pdf 9,96MB
WeightNameValue
1000 Titel
  • Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model
1000 Autor/in
  1. Dutta, Rinku |
  2. Khalil, Roukiah |
  3. Mayilsamy, Karthick |
  4. Green, Ryan |
  5. Howell, Mark |
  6. Bharadwaj, Srinivas |
  7. Mohapatra, Shyam S. |
  8. Mohapatra, Subhra |
1000 Verlag
  • Frontiers Media S.A.
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-07-26
1000 Erschienen in
1000 Quellenangabe
  • 12:706133
1000 Copyrightjahr
  • 2021
1000 Embargo
  • 2022-01-28
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.3389/fimmu.2021.706133 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350740/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Abstract/Summary
  • <jats:p>The axis of Programmed cell death-1 receptor (PD-1) with its ligand (PD-L1) plays a critical role in colorectal cancer (CRC) in escaping immune surveillance, and blocking this axis has been found to be effective in a subset of patients. Although blocking PD-L1 has been shown to be effective in 5–10% of patients, the majority of the cohorts show resistance to this checkpoint blockade (CB) therapy. Multiple factors assist in the growth of resistance to CB, among which T cell exhaustion and immunosuppressive effects of immune cells in the tumor microenvironment (TME) play a critical role along with other tumor intrinsic factors. We have previously shown the polyketide antibiotic, Mithramycin-A (Mit-A), an effective agent in killing cancer stem cells (CSCs) <jats:italic>in vitro</jats:italic> and <jats:italic>in vivo</jats:italic> in a subcutaneous murine model. Since TME plays a pivotal role in CB therapy, we tested the immunomodulatory efficacy of Mit-A with anti-PD-L1 mAb (αPD-L1) combination therapy in an immunocompetent MC38 syngeneic orthotopic CRC mouse model. Tumors and spleens were analyzed by flow cytometry for the distinct immune cell populations affected by the treatment, in addition to RT-PCR for tumor samples. We demonstrated the combination treatment decreases tumor growth, thus increasing the effectiveness of the CB. Mit-A in the presence of αPD-L1 significantly increased CD8<jats:sup>+</jats:sup> T cell infiltration and decreased immunosuppressive granulocytic myeloid-derived suppressor cells and anti-inflammatory macrophages in the TME. Our results revealed Mit-A in combination with αPD-L1 has the potential for augmented CB therapy by turning an immunologically “cold” into “hot” TME in CRC.</jats:p>
1000 Sacherschließung
lokal Female [MeSH]
lokal Immunology
lokal Mice, Inbred C57BL [MeSH]
lokal PD-L1
lokal colorectal cancer
lokal Mithramycin-A
lokal Plicamycin/analogs
lokal Animals [MeSH]
lokal Mice [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/pharmacology [MeSH]
lokal Colorectal Neoplasms/pathology [MeSH]
lokal combination therapy
lokal Colorectal Neoplasms/immunology [MeSH]
lokal Disease Models, Animal [MeSH]
lokal Immune Checkpoint Inhibitors/pharmacology [MeSH]
lokal Plicamycin/pharmacology [MeSH]
lokal orthotopic tumor
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/RHV0dGEsIFJpbmt1|https://frl.publisso.de/adhoc/uri/S2hhbGlsLCBSb3VraWFo|https://frl.publisso.de/adhoc/uri/TWF5aWxzYW15LCBLYXJ0aGljaw==|https://frl.publisso.de/adhoc/uri/R3JlZW4sIFJ5YW4=|https://frl.publisso.de/adhoc/uri/SG93ZWxsLCBNYXJr|https://frl.publisso.de/adhoc/uri/QmhhcmFkd2FqLCBTcmluaXZhcw==|https://frl.publisso.de/adhoc/uri/TW9oYXBhdHJhLCBTaHlhbSBTLg==|https://frl.publisso.de/adhoc/uri/TW9oYXBhdHJhLCBTdWJocmE=
1000 Hinweis
  • DeepGreen-ID: e615fd13fb0b421ebdab56abcf1e04a4 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. U.S. Department of Veterans Affairs |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer U.S. Department of Veterans Affairs |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6478172.rdf
1000 Erstellt am 2024-05-21T13:31:37.068+0200
1000 Erstellt von 322
1000 beschreibt frl:6478172
1000 Zuletzt bearbeitet 2024-05-22T10:07:23.024+0200
1000 Objekt bearb. Wed May 22 10:07:23 CEST 2024
1000 Vgl. frl:6478172
1000 Oai Id
  1. oai:frl.publisso.de:frl:6478172 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source